nach oben

Drugs

Erschienen in:

01.07.2016 | Leading Article

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation

verfasst von: Hsing-Chuan Tsai, May H. Han

Erschienen in: Drugs | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are ubiquitously expressed. S1P-S1PR signaling has been well characterized in immune trafficking and activation in innate and adaptive immune systems. However, the full extent of its involvement in the pathogenesis of autoimmune diseases is not well understood. FTY720 (fingolimod), a non-selective S1PR modulator, significantly decreased annualized relapse rates in relapsing-remitting multiple sclerosis (MS). FTY720, which primarily targets S1P receptor 1 as a functional antagonist, arrests lymphocyte egress from secondary lymphoid tissues and reduces neuroinflammation in the central nervous system (CNS). Recent studies suggest that FTY720 also decreases astrogliosis and promotes oligodendrocyte differentiation within the CNS and may have therapeutic benefit to prevent brain atrophy. Since S1P signaling is involved in multiple immune functions, therapies targeting S1P axis may be applicable to treat autoimmune diseases other than MS. Currently, over a dozen selective S1PR and S1P pathway modulators with potentially superior therapeutic efficacy and better side-effect profiles are in the pipeline of drug development. Furthermore, newly characterized molecules such as apolipoprotein M (ApoM) (S1P chaperon) and SPNS2 (S1P transporter) are also potential targets for treatment of autoimmune diseases. Finally, the application of therapies targeting S1P and S1P signaling pathways may be expanded to treat several other immune-mediated disorders (such as post-infectious diseases, post-stroke and post-stroke dementia) and inflammatory conditions beyond their application in primary autoimmune diseases.

Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. Nat Rev Immunol. 2011;11(6):403–15. doi:10.1038/nri2974.PubMedPubMedCentralCrossRef

Prager B, Spampinato SF, Ransohoff RM. Sphingosine 1-phosphate signaling at the blood-brain barrier. Trends Mol Med. 2015;21(6):354–63. doi:10.1016/j.molmed.2015.03.006.PubMedCrossRef

Spiegel S, Milstien S. Functions of the multifaceted family of sphingosine kinases and some close relatives. J Biol Chem. 2007;282(4):2125–9. doi:10.1074/jbc.R600028200.PubMedCrossRef

Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014;510(7503):58–67. doi:10.1038/nature13475.PubMedPubMedCentralCrossRef

Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8(12):1295–301. doi:10.1038/ni1545.PubMedCrossRef

Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol. 2008;8(10):753–63. doi:10.1038/nri2400.PubMedPubMedCentralCrossRef

Garris CS, Wu L, Acharya S, Arac A, Blaho VA, Huang Y, et al. Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol. 2013;14(11):1166–72. doi:10.1038/ni.2730.PubMedPubMedCentralCrossRef

Liu G, Yang K, Burns S, Shrestha S, Chi H. The S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and T(reg) cells. Nat Immunol. 2010;11(11):1047–56. doi:10.1038/ni.1939.PubMedPubMedCentralCrossRef

Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev. 2006;212:217–37. doi:10.1111/j.0105-2896.2006.00421.x.PubMedCrossRef

10.

Steinman L, Merrill JT, McInnes IB, Peakman M. Optimization of current and future therapy for autoimmune diseases. Nat Med. 2012;18(1):59–65. doi:10.1038/nm.2625.PubMedCrossRef

11.

Snider AJ. Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease. Int J Clin Rheumatol. 2013;. doi:10.2217/ijr.13.40.

12.

Brunkhorst R, Vutukuri R, Pfeilschifter W. Fingolimod for the treatment of neurological diseases-state of play and future perspectives. Front Cell Neurosci. 2014;8:283. doi:10.3389/fncel.2014.00283.PubMedPubMedCentralCrossRef

13.

Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759–77. doi:10.1002/ana.22426.PubMedCrossRef

14.

Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol. 2012;30:69–94. doi:10.1146/annurev-immunol-020711-075011.PubMedCrossRef

15.

Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, et al. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008;102(6):669–76. doi:10.1161/CIRCRESAHA.107.165845.PubMedPubMedCentralCrossRef

16.

Olivera A, Allende ML, Proia RL. Shaping the landscape: metabolic regulation of S1P gradients. Biochim Biophys Acta. 2013;1831(1):193–202. doi:10.1016/j.bbalip.2012.06.007.PubMedCrossRef

17.

Pham TH, Baluk P, Xu Y, Grigorova I, Bankovich AJ, Pappu R, et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning. J Exp Med. 2010;207(1):17–27. doi:10.1084/jem.20091619.PubMedPubMedCentralCrossRef

18.

Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science. 2005;309(5741):1735–9. doi:10.1126/science.1113640.PubMedCrossRef

19.

Argraves KM, Argraves WS. HDL serves as a S1P signaling platform mediating a multitude of cardiovascular effects. J Lipid Res. 2007;48(11):2325–33. doi:10.1194/jlr.R700011-JLR200.PubMedCrossRef

20.

Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA. 2011;108(23):9613–8. doi:10.1073/pnas.1103187108.PubMedPubMedCentralCrossRef

21.

Blaho VA, Galvani S, Engelbrecht E, Liu C, Swendeman SL, Kono M, et al. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature. 2015;523(7560):342–6. doi:10.1038/nature14462.PubMedPubMedCentralCrossRef

22.

Galvani S, Sanson M, Blaho VA, Swendeman SL, Conger H, Dahlback B, et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal. 2015;8(389):79. doi:10.1126/scisignal.aaa2581.CrossRef

23.

Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science. 2007;316(5822):295–8. doi:10.1126/science.1139221.PubMedCrossRef

24.

Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, Hait NC, et al. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J Off Publ Fed Am Soc Exp Biol. 2013;27(3):1001–11. doi:10.1096/fj.12-219618.

25.

Takada K, Wang X, Hart GT, Odumade OA, Weinreich MA, Hogquist KA, et al. Kruppel-like factor 2 is required for trafficking but not quiescence in postactivated T cells. J Immunol. 2011;186(2):775–83. doi:10.4049/jimmunol.1000094.PubMedCrossRef

26.

Carlson CM, Endrizzi BT, Wu J, Ding X, Weinreich MA, Walsh ER, et al. Kruppel-like factor 2 regulates thymocyte and T-cell migration. Nature. 2006;442(7100):299–302. doi:10.1038/nature04882.PubMedCrossRef

27.

Arnon TI, Xu Y, Lo C, Pham T, An J, Coughlin S, et al. GRK2-dependent S1PR1 desensitization is required for lymphocytes to overcome their attraction to blood. Science. 2011;333(6051):1898–903. doi:10.1126/science.1208248.PubMedPubMedCentralCrossRef

28.

Grigorova IL, Schwab SR, Phan TG, Pham TH, Okada T, Cyster JG. Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells. Nat Immunol. 2009;10(1):58–65. doi:10.1038/ni.1682.PubMedCrossRef

29.

Pham TH, Okada T, Matloubian M, Lo CG, Cyster JG. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity. 2008;28(1):122–33. doi:10.1016/j.immuni.2007.11.017.PubMedCrossRef

30.

Thangada S, Khanna KM, Blaho VA, Oo ML, Im DS, Guo C, et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med. 2010;207(7):1475–83. doi:10.1084/jem.20091343.PubMedPubMedCentralCrossRef

31.

Garris CS, Blaho VA, Hla T, Han MH. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond. Immunology. 2014;142(3):347–53. doi:10.1111/imm.12272.PubMedPubMedCentralCrossRef

32.

Sebzda E, Zou Z, Lee JS, Wang T, Kahn ML. Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns. Nat Immunol. 2008;9(3):292–300. doi:10.1038/ni1565.PubMedCrossRef

33.

Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature. 2006;440(7083):540–4. doi:10.1038/nature04606.PubMedCrossRef

34.

Bankovich AJ, Shiow LR, Cyster JG. CD69 suppresses sphingosine 1-phosophate receptor-1 (S1P1) function through interaction with membrane helix 4. J Biol Chem. 2010;285(29):22328–37. doi:10.1074/jbc.M110.123299.PubMedPubMedCentralCrossRef

35.

Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedoui S, et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol. 2015;194(5):2059–63. doi:10.4049/jimmunol.1402256.PubMedCrossRef

36.

Arnon TI, Cyster JG. Blood, sphingosine-1-phosphate and lymphocyte migration dynamics in the spleen. Curr Top Microbiol Immunol. 2014;378:107–28. doi:10.1007/978-3-319-05879-5_5.PubMed

37.

Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280(44):37118–29. doi:10.1074/jbc.M502207200.PubMedCrossRef

38.

Venkataraman K, Thangada S, Michaud J, Oo ML, Ai Y, Lee YM, et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J. 2006;397(3):461–71. doi:10.1042/BJ20060251.PubMedPubMedCentralCrossRef

39.

Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA. 1998;95(24):14196–201.PubMedPubMedCentralCrossRef

40.

Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084–8. doi:10.1038/nature09128.PubMedPubMedCentralCrossRef

41.

Adada MM, Orr-Gandy KA, Snider AJ, Canals D, Hannun YA, Obeid LM, et al. Sphingosine kinase 1 regulates tumor necrosis factor-mediated RANTES induction through p38 mitogen-activated protein kinase but independently of nuclear factor kappaB activation. J Biol Chem. 2013;288(38):27667–79. doi:10.1074/jbc.M113.489443.PubMedPubMedCentralCrossRef

42.

Xiong Y, Lee HJ, Mariko B, Lu YC, Dannenberg AJ, Haka AS, et al. Sphingosine kinases are not required for inflammatory responses in macrophages. J Biol Chem. 2013;288(45):32563–73. doi:10.1074/jbc.M113.483750.PubMedPubMedCentralCrossRef

43.

Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23(1):107–20. doi:10.1016/j.ccr.2012.11.013.PubMedCrossRef

44.

Maines LW, Fitzpatrick LR, Green CL, Zhuang Y, Smith CD. Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn’s disease. Inflammopharmacology. 2010;18(2):73–85. doi:10.1007/s10787-010-0032-x.PubMedCrossRef

45.

Baker DA, Barth J, Chang R, Obeid LM, Gilkeson GS. Genetic sphingosine kinase 1 deficiency significantly decreases synovial inflammation and joint erosions in murine TNF-alpha-induced arthritis. J Immunol. 2010;185(4):2570–9. doi:10.4049/jimmunol.1000644.PubMedPubMedCentralCrossRef

46.

Fitzpatrick LR, Green C, Frauenhoffer EE, French KJ, Zhuang Y, Maines LW, et al. Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase. Inflammopharmacology. 2011;19(2):75–87. doi:10.1007/s10787-010-0060-6.PubMedCrossRef

47.

Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325(5945):1254–7. doi:10.1126/science.1176709.PubMedPubMedCentralCrossRef

48.

Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, Smith JD, et al. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(1):81–5. doi:10.1161/ATVBAHA.110.213496.PubMedCrossRef

49.

Weigert A, Weis N, Brune B. Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology. 2009;214(9–10):748–60. doi:10.1016/j.imbio.2009.06.003.PubMedCrossRef

50.

Arlt O, Schwiebs A, Japtok L, Ruger K, Katzy E, Kleuser B, et al. Sphingosine-1-phosphate modulates dendritic cell function: focus on non-migratory effects in vitro and in vivo. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2014;34(1):27–44. doi:10.1159/000362982.CrossRef

51.

Idzko M, Panther E, Corinti S, Morelli A, Ferrari D, Herouy Y, et al. Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses. FASEB J Off Publ Fed Am Soc Exp Biol. 2002;16(6):625–7.

52.

Muller H, Hofer S, Kaneider N, Neuwirt H, Mosheimer B, Mayer G, et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol. 2005;35(2):533–45. doi:10.1002/eji.200425556.PubMedCrossRef

53.

Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature. 2008;452(7187):654–8. doi:10.1038/nature06663.PubMedCrossRef

54.

Dillmann C, Mora J, Olesch C, Brune B, Weigert A. S1PR4 is required for plasmacytoid dendritic cell differentiation. Biol Chem. 2015;396(6–7):775–82. doi:10.1515/hsz-2014-0271.PubMed

55.

Schulze T, Golfier S, Tabeling C, Rabel K, Graler MH, Witzenrath M, et al. Sphingosine-1-phospate receptor 4 (S1P(4)) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model. FASEB J Off Publ Fed Am Soc Exp Biol. 2011;25(11):4024–36. doi:10.1096/fj.10-179028.

56.

Liu G, Burns S, Huang G, Boyd K, Proia RL, Flavell RA, et al. The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol. 2009;10(7):769–77. doi:10.1038/ni.1743.PubMedPubMedCentralCrossRef

57.

Huang MC, Watson SR, Liao JJ, Goetzl EJ. Th17 augmentation in OTII TCR plus T cell-selective type 1 sphingosine 1-phosphate receptor double transgenic mice. J Immunol. 2007;178(11):6806–13.PubMedCrossRef

58.

Liao JJ, Huang MC, Goetzl EJ. Cutting edge: alternative signaling of Th17 cell development by sphingosine 1-phosphate. J Immunol. 2007;178(9):5425–8.PubMedCrossRef

59.

Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010;16(12):1421–8. doi:10.1038/nm.2250.PubMedPubMedCentralCrossRef

60.

Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014;55(8):1596–608. doi:10.1194/jlr.R046300.PubMedPubMedCentralCrossRef

61.

Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Investig. 2009;119(7):1871–9.PubMedPubMedCentral

62.

Dudek SM, Chiang ET, Camp SM, Guo Y, Zhao J, Brown ME, et al. Abl tyrosine kinase phosphorylates nonmuscle Myosin light chain kinase to regulate endothelial barrier function. Mol Biol Cell. 2010;21(22):4042–56. doi:10.1091/mbc.E09-10-0876.PubMedPubMedCentralCrossRef

63.

Niessen F, Furlan-Freguia C, Fernandez JA, Mosnier LO, Castellino FJ, Weiler H, et al. Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood. 2009;113(12):2859–66. doi:10.1182/blood-2008-12-192385.PubMedPubMedCentralCrossRef

64.

Sammani S, Moreno-Vinasco L, Mirzapoiazova T, Singleton PA, Chiang ET, Evenoski CL, et al. Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung. Am J Respir Cell Mol Biol. 2010;43(4):394–402. doi:10.1165/rcmb.2009-0223OC.PubMedCrossRef

65.

Spampinato SF, Obermeier B, Cotleur A, Love A, Takeshita Y, Sano Y, et al. Sphingosine 1 phosphate at the blood brain barrier: can the modulation of S1P receptor 1 influence the response of endothelial cells and astrocytes to inflammatory stimuli? PLoS One. 2015;10(7):e0133392. doi:10.1371/journal.pone.0133392.PubMedPubMedCentralCrossRef

66.

Kulakowska A, Zendzian-Piotrowska M, Baranowski M, Kononczuk T, Drozdowski W, Gorski J, et al. Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci Lett. 2010;477(3):149–52. doi:10.1016/j.neulet.2010.04.052.PubMedCrossRef

67.

Choi JW, Gardell SE, Herr DR, Rivera R, Lee CW, Noguchi K, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA. 2011;108(2):751–6. doi:10.1073/pnas.1014154108.PubMedCrossRef

68.

Kitano M, Hla T, Sekiguchi M, Kawahito Y, Yoshimura R, Miyazawa K, et al. Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum. 2006;54(3):742–53. doi:10.1002/art.21668.PubMedCrossRef

69.

Kimura A, Ohmori T, Kashiwakura Y, Ohkawa R, Madoiwa S, Mimuro J, et al. Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain. Stroke J Cereb Circ. 2008;39(12):3411–7. doi:10.1161/STROKEAHA.108.514612.CrossRef

70.

Snider AJ, Kawamori T, Bradshaw SG, Orr KA, Gilkeson GS, Hannun YA, et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J Off Publ Fed Am Soc Exp Biol. 2009;23(1):143–52. doi:10.1096/fj.08-118109.

71.

Kunkel GT, Maceyka M, Milstien S, Spiegel S. Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013;12(9):688–702. doi:10.1038/nrd4099.PubMedPubMedCentralCrossRef

72.

Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9(11):883–97. doi:10.1038/nrd3248.PubMedCrossRef

73.

Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi:10.1056/NEJMoa0909494.PubMedCrossRef

74.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15. doi:10.1056/NEJMoa0907839.PubMedCrossRef

75.

Kappos L, O’Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84(15):1582–91. doi:10.1212/WNL.0000000000001462.PubMedPubMedCentralCrossRef

76.

Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2016;87(5):468–75. doi:10.1136/jnnp-2015-310597.PubMedCrossRef

77.

Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 2003;554(1–2):189–93.PubMedCrossRef

78.

Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem. 2003;278(48):47408–15. doi:10.1074/jbc.M307687200.PubMedCrossRef

79.

Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453–7. doi:10.1074/jbc.C200176200.PubMedCrossRef

80.

Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101. doi:10.1097/WNF.0b013e3181cbf825.PubMedPubMedCentralCrossRef

81.

Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology. 2010;75(5):403–10. doi:10.1212/WNL.0b013e3181ebdd64.PubMedCrossRef

82.

Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, et al. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol. 2014;268(1–2):95–8. doi:10.1016/j.jneuroim.2014.01.008.PubMedCrossRef

83.

Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler. 2014;20(13):1704–13. doi:10.1177/1352458514532317.PubMedCrossRef

84.

Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol. 2008;63(1):61–71. doi:10.1002/ana.21227.PubMedCrossRef

85.

Zhang J, Zhang ZG, Li Y, Ding X, Shang X, Lu M, et al. Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Neurobiol Dis. 2015;76:57–66. doi:10.1016/j.nbd.2015.01.006.PubMedCrossRef

86.

Bourdette D, Gilden D. Fingolimod and multiple sclerosis: four cautionary tales. Neurology. 2012;79(19):1942–3. doi:10.1212/WNL.0b013e3182735edf.PubMedCrossRef

87.

Visser F, Wattjes MP, Pouwels PJ, Linssen WH, van Oosten BW. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2012;79(19):2000–3. doi:10.1212/WNL.0b013e3182735cb3.PubMedCrossRef

88.

Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011;76(8 Suppl 3):S20–7. doi:10.1212/WNL.0b013e31820db341.PubMedCrossRef

89.

Obinata H, Gutkind S, Stitham J, Okuno T, Yokomizo T, Hwa J, et al. Individual variation of human S1P1 coding sequence leads to heterogeneity in receptor function and drug interactions. J Lipid Res. 2014;55(12):2665–75. doi:10.1194/jlr.P054163.PubMedPubMedCentralCrossRef

90.

International Multiple Sclerosis Genetics C. Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. Am J Hum Genet. 2013;92(6):854–65. doi:10.1016/j.ajhg.2013.04.019.CrossRef

91.

Fischer I, Alliod C, Martinier N, Newcombe J, Brana C, Pouly S. Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS One. 2011;6(8):e23905. doi:10.1371/journal.pone.0023905.PubMedPubMedCentralCrossRef

92.

Brana C, Frossard MJ, PesciniGobert R, Martinier N, Boschert U, Seabrook TJ. Immunohistochemical detection of sphingosine-1-phosphate receptor 1 and 5 in human multiple sclerosis lesions. Neuropathol Appl Neurobiol. 2014;40(5):564–78. doi:10.1111/nan.12048.PubMedCrossRef

93.

Willis MA, Cohen JA. Fingolimod therapy for multiple sclerosis. Semin Neurol. 2013;33(1):37–44. doi:10.1055/s-0033-1343794.PubMedCrossRef

94.

Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology. 2013;80(2):139–44. doi:10.1212/WNL.0b013e31827b9132.PubMedPubMedCentralCrossRef

95.

Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67. doi:10.1016/S1474-4422(13)70102-9.PubMedCrossRef

96.

Krosser S, Wolna P, Fischer TZ, Boschert U, Stoltz R, Zhou M, et al. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm. J Clin Pharmacol. 2015;55(9):1051–60. doi:10.1002/jcph.513.PubMedCrossRef

97.

Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014;85(11):1198–208. doi:10.1136/jnnp-2013-307282.PubMedPubMedCentralCrossRef

98.

Quancard J, Bollbuck B, Janser P, Angst D, Berst F, Buehlmayer P, et al. A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol. 2012;19(9):1142–51. doi:10.1016/j.chembiol.2012.07.016.PubMedCrossRef

99.

Kamada K, Arita N, Tsubaki T, Takubo N, Fujino T, Soga Y, et al. Expression of sphingosine kinase 2 in synovial fibroblasts of rheumatoid arthritis contributing to apoptosis by a sphingosine analogue, FTY720. Pathol Int. 2009;59(6):382–9. doi:10.1111/j.1440-1827.2009.02381.x.PubMedCrossRef

100.

Matsuura M, Imayoshi T, Chiba K, Okumoto T. Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats. Inflamm Res Off J Eur Histamine Res Soc [et al]. 2000;49(8):404–10.

101.

Tsunemi S, Iwasaki T, Kitano S, Imado T, Miyazawa K, Sano H. Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Clin Immunol. 2010;136(2):197–204. doi:10.1016/j.clim.2010.03.428.PubMedCrossRef

102.

Michaud J, Kohno M, Proia RL, Hla T. Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice. FEBS Lett. 2006;580(19):4607–12. doi:10.1016/j.febslet.2006.07.035.PubMedCrossRef

103.

Lai WQ, Irwan AW, Goh HH, Melendez AJ, McInnes IB, Leung BP. Distinct roles of sphingosine kinase 1 and 2 in murine collagen-induced arthritis. J Immunol. 2009;183(3):2097–103. doi:10.4049/jimmunol.0804376.PubMedCrossRef

104.

Baker DA, Eudaly J, Smith CD, Obeid LM, Gilkeson GS. Impact of sphingosine kinase 2 deficiency on the development of TNF-alpha-induced inflammatory arthritis. Rheumatol Int. 2013;33(10):2677–81. doi:10.1007/s00296-012-2493-2.PubMedCrossRef

105.

Dickson MA, Carvajal RD, Merrill AH Jr, Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(8):2484–92. doi:10.1158/1078-0432.CCR-10-2323.CrossRef

106.

Bagdanoff JT, Donoviel MS, Nouraldeen A, Carlsen M, Jessop TC, Tarver J, et al. Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem. 2010;53(24):8650–62. doi:10.1021/jm101183p.PubMedCrossRef

107.

Fleischmann RM, Poiley JE, Stoilov R, Strand V, Freiman J, Oravecz T, Sands A. The Oral S1P Lyase Inhibitor LX3305 (LX2931) Demonstrates favorable safety and potential clinical benefit at 12-weeks in a phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy [abstract]. Arthritis Rheum. 2011;63(Suppl 10):2593.

108.

Montrose DC, Scherl EJ, Bosworth BP, Zhou XK, Jung B, Dannenberg AJ, et al. S1P(1) localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res. 2013;54(3):843–51. doi:10.1194/jlr.M034108.PubMedPubMedCentralCrossRef

109.

Snider AJ, Ali WH, Sticca JA, Coant N, Ghaleb AM, Kawamori T, et al. Distinct roles for hematopoietic and extra-hematopoietic sphingosine kinase-1 in inflammatory bowel disease. PLoS One. 2014;9(12):e113998. doi:10.1371/journal.pone.0113998.PubMedPubMedCentralCrossRef

110.

Song J, Matsuda C, Kai Y, Nishida T, Nakajima K, Mizushima T, et al. A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther. 2008;324(1):276–83. doi:10.1124/jpet.106.119172.PubMedCrossRef

111.

Sandborn WJ, Feagan BG, Wolf DC, D’Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374(18):1754–62. doi:10.1056/NEJMoa1513248.PubMedCrossRef

112.

Buzard DJ, Kim SH, Lopez L, Kawasaki A, Zhu X, Moody J et al. Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor. ACS Med Chem Lett. 2014;5(12):1313–7. doi:10.1021/ml500389m.PubMedPubMedCentralCrossRef

113.

Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–73. doi:10.1038/nature05663.PubMedCrossRef

114.

Kim DS, Kim SY, Kleuser B, Schafer-Korting M, Kim KH, Park KC. Sphingosine-1-phosphate inhibits human keratinocyte proliferation via Akt/protein kinase B inactivation. Cell Signal. 2004;16(1):89–95.PubMedCrossRef

115.

Schaper K, Dickhaut J, Japtok L, Kietzmann M, Mischke R, Kleuser B, et al. Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis. J Dermatol Sci. 2013;71(1):29–36. doi:10.1016/j.jdermsci.2013.03.006.PubMedCrossRef

116.

Checa A, Xu N, Sar DG, Haeggstrom JZ, Stahle M, Wheelock CE. Circulating levels of sphingosine-1-phosphate are elevated in severe, but not mild psoriasis and are unresponsive to anti-TNF-alpha treatment. Sci Rep. 2015;5:12017. doi:10.1038/srep12017.PubMedPubMedCentralCrossRef

117.

Vaclavkova A, Chimenti S, Arenberger P, Hollo P, Sator PG, Burcklen M, et al. Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;384(9959):2036–45. doi:10.1016/S0140-6736(14)60803-5.PubMedCrossRef

118.

Samuvel DJ, Saxena N, Dhindsa JS, Singh AK, Gill GS, Grobelny DW, et al. AKP-11—A Novel S1P1 agonist with favorable safety profile attenuates experimental autoimmune encephalomyelitis in rat model of multiple sclerosis. PLoS One. 2015;10(10):e0141781. doi:10.1371/journal.pone.0141781.PubMedPubMedCentralCrossRef

119.

Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–21. doi:10.1056/NEJMra1100359.PubMedCrossRef

120.

Watson L, Tullus K, Marks SD, Holt RC, Pilkington C, Beresford MW. Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus. J Clin Immunol. 2012;32(5):1019–25. doi:10.1007/s10875-012-9710-3.PubMedCrossRef

121.

Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, et al. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus. J Rheumatol. 2002;29(4):707–16.PubMed

122.

Ando S, Amano H, Amano E, Minowa K, Watanabe T, Nakano S, et al. FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice. Biochem Biophys Res Commun. 2010;394(3):804–10. doi:10.1016/j.bbrc.2010.03.078.PubMedCrossRef

123.

Wenderfer SE, Stepkowski SM, Braun MC. Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist. Kidney Int. 2008;74(10):1319–26. doi:10.1038/ki.2008.396.PubMedPubMedCentralCrossRef

124.

Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflamm. 2011;8:127. doi:10.1186/1742-2094-8-127.CrossRef

125.

Donoviel MS, Hait NC, Ramachandran S, Maceyka M, Takabe K, Milstien S, et al. Spinster 2, a sphingosine-1-phosphate transporter, plays a critical role in inflammatory and autoimmune diseases. FASEB J Off Publ Fed Am Soc Exp Biol. 2015;29(12):5018–28. doi:10.1096/fj.15-274936.

126.

Kamel H, Iadecola C. Brain-immune interactions and ischemic stroke: clinical implications. Arch Neurol. 2012;69(5):576–81. doi:10.1001/archneurol.2011.3590.PubMedPubMedCentralCrossRef

127.

Magnus T, Wiendl H, Kleinschnitz C. Immune mechanisms of stroke. Curr Opin Neurol. 2012;25(3):334–40. doi:10.1097/WCO.0b013e328352ede6.PubMedCrossRef

128.

Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci USA. 2014;111(51):18315–20. doi:10.1073/pnas.1416166111.PubMedPubMedCentralCrossRef

129.

Fu Y, Hao J, Zhang N, Ren L, Sun N, Li YJ, et al. Fingolimod for the treatment of intracerebral hemorrhage: a 2-arm proof-of-concept study. JAMA Neurol. 2014;71(9):1092–101. doi:10.1001/jamaneurol.2014.1065.PubMedCrossRef

130.

Wei Y, Yemisci M, Kim HH, Yung LM, Shin HK, Hwang SK, et al. Fingolimod provides long-term protection in rodent models of cerebral ischemia. Ann Neurol. 2011;69(1):119–29. doi:10.1002/ana.22186.PubMedCrossRef

131.

Kraft P, Gob E, Schuhmann MK, Gobel K, Deppermann C, Thielmann I, et al. FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke J Cereb Circ. 2013;44(11):3202–10. doi:10.1161/STROKEAHA.113.002880.CrossRef

132.

Brunkhorst R, Kanaan N, Koch A, Ferreiros N, Mirceska A, Zeiner P, et al. FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS One. 2013;8(7):e70124. doi:10.1371/journal.pone.0070124.PubMedPubMedCentralCrossRef

133.

Lu L, Barfejani AH, Qin T, Dong Q, Ayata C, Waeber C. Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage. Brain Res. 2014;1555:89–96. doi:10.1016/j.brainres.2014.01.048.PubMedPubMedCentralCrossRef

134.

Rolland WB, Lekic T, Krafft PR, Hasegawa Y, Altay O, Hartman R, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol. 2013;241:45–55. doi:10.1016/j.expneurol.2012.12.009.PubMedCrossRef

Titel: Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation
verfasst von: Hsing-Chuan Tsai
May H. Han
Publikationsdatum: 01.07.2016
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 11/2016
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-016-0603-2

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Olmutinib: First Global Approval

Secukinumab: A Review in Psoriatic Arthritis

Erratum to: Reslizumab: First Global Approval

Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management

Migalastat: First Global Approval

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy